Arrowhead Pharmaceuticals

Sanofi
Biotech

Sanofi pens $395M China pact for Arrowhead metabolic med

Sanofi is handing over $130 million upfront for the China rights to Arrowhead’s rare metabolic disease drug currently being considered for approval.
James Waldron Aug 1, 2025 7:21am
timer sand clocks time

Arrowhead meets $100M milestone, awaits Sarepta payment

Jul 28, 2025 3:10pm
Photo of Wall Street street sign with american flags in the background

Arrowhead reassures investors about pact with troubled Sarepta

Jul 23, 2025 10:13am
Kidneys brightly lit

Arrowhead shares ‘select’ data for RNAi asset in kidney trial

Mar 10, 2025 11:55am
graphic image of different colored hands shaking

Sarepta, Arrowhead ink $1B-plus deal for seven programs

Nov 26, 2024 11:18am
photo of a royal flush laid out on the poker table with chips scattered nearby

Arrowhead posts phase 3 data ahead of market clash with Ionis

Sep 3, 2024 9:27am